HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Pathology3 papers

Disease caused by Heterocheiloidea

Last edited: 1 h ago

Overview

Lathosterolosis (LS) is a rare genetic disorder characterized by a defect in cholesterol biosynthesis due to the deficiency of sterol-C5-desaturase enzyme. This condition leads to multiple malformations, intellectual disability, and significant liver involvement, often presenting with severe developmental and systemic complications. Primarily affecting infants and young children, LS underscores the critical importance of early diagnosis and intervention to mitigate long-term morbidity. Understanding LS is crucial for clinicians to recognize and manage this rare condition effectively in day-to-day practice 2.

Pathophysiology

Lathosterolosis arises from a genetic mutation that impairs the sterol-C5-desaturase enzyme, a key player in the cholesterol biosynthesis pathway. This enzymatic deficiency results in an accumulation of lathosterol, a precursor sterol, while cholesterol levels remain critically low. At the cellular level, the lack of adequate cholesterol disrupts membrane integrity and function, affecting multiple organ systems. Specifically, the brain and liver are profoundly impacted due to their high cholesterol demands for proper development and function. The accumulation of lathosterol and deficiency in cholesterol contribute to the characteristic malformations and neurological deficits observed in affected individuals 2.

Epidemiology

Lathosterolosis is exceedingly rare, with only a handful of cases reported globally. The exact incidence and prevalence are not well-defined due to the rarity of the condition. Reported cases predominantly involve infants and young children, suggesting a congenital onset. There is no clear sex predilection noted in the limited literature available. Geographic distribution appears sporadic, with cases identified across different regions without apparent clustering, indicating no specific environmental or geographic risk factors 2.

Clinical Presentation

The clinical presentation of lathosterolosis is marked by a constellation of severe symptoms including multiple congenital malformations, intellectual disability, and liver dysfunction. Common features include neural tube defects, craniofacial anomalies such as cleft palate or lip, limb malformations, and growth retardation. Liver involvement often manifests as hepatomegaly or elevated liver enzymes, reflecting significant organ dysfunction. Pathological examinations may reveal mucolipidosis-like inclusions in some cases, though this feature is not consistently observed across all reported cases, suggesting variability in clinical expression 2.

Diagnosis

Diagnosing lathosterolosis involves a comprehensive approach combining clinical evaluation with biochemical and genetic testing. The diagnostic workup typically includes:

  • Biochemical Analysis: Measurement of sterol profiles in blood or fibroblasts, focusing on elevated lathosterol levels and reduced cholesterol levels.
  • Genetic Testing: Identification of mutations in the CYP51A1 gene (encoding sterol-C5-desaturase) through whole exome sequencing or targeted gene panel analysis.
  • Histological Examination: Skin biopsy or autopsy samples to assess for characteristic ultrastructural findings such as lamellar bodies.

    • Specific Criteria and Tests:

  • Elevated lathosterol levels in plasma or fibroblasts (typically >10x normal levels).
  • Reduced cholesterol levels in plasma (often <50% of normal levels).
  • Genetic confirmation of mutations in the CYP51A1 gene.
  • Presence of characteristic ultrastructural features on electron microscopy (lamellar bodies).

    • Differential Diagnosis:

  • Smith-Lemli-Opitz Syndrome (SLOS): Distinguished by similar sterol abnormalities but different genetic mutations and often more pronounced developmental issues.
  • Other Congenital Malformation Syndromes: Differentiating based on specific clinical features and genetic testing results.

    • Management

    The management of lathosterolosis is multifaceted, focusing on supportive care and addressing specific organ dysfunctions.

    First-Line Management

  • Supportive Care: Early intervention for developmental delays through physical, occupational, and speech therapy.
  • Nutritional Support: Ensuring adequate intake of cholesterol-rich foods under medical supervision to mitigate some symptoms.
  • Liver Function Monitoring: Regular assessment of liver enzymes and imaging to manage hepatomegaly and prevent complications.

    • Specific Interventions:

  • Cholesterol supplementation (e.g., 100 mg/day, adjusted based on response and monitoring).
  • Regular developmental assessments every 3-6 months.
  • Liver function tests every 6 months.

    • Second-Line Management

  • Pharmacological Interventions: In cases of severe symptoms, consider medications to manage specific complications such as anticonvulsants for seizures or hepatoprotective agents.
  • Multidisciplinary Team: Collaboration with pediatricians, geneticists, hepatologists, and neurologists to tailor comprehensive care plans.

    • Specific Interventions:

  • Anticonvulsants (e.g., valproate, tigated based on seizure type and response).
  • Hepatoprotective agents (e.g., ursodeoxycholic acid, as prescribed by a hepatologist).

    • Refractory Cases

  • Specialist Referral: Escalation to pediatric metabolic specialists or genetic counselors for advanced management strategies.
  • Clinical Trials: Participation in clinical trials targeting cholesterol biosynthesis pathways if available.

    • Specific Interventions:

  • Referral to pediatric metabolic specialists.
  • Consideration of experimental therapies under clinical trial conditions.

    • Complications

    Common complications of lathosterolosis include:
  • Neurodevelopmental Delays: Persistent intellectual disability requiring lifelong support.
  • Hepatic Dysfunction: Progressive liver disease necessitating monitoring and potential transplantation in severe cases.
  • Seizures: Neurological complications requiring anticonvulsive therapy.

    • Management Triggers:

  • Elevated liver enzymes or imaging evidence of hepatomegaly.
  • Appearance of seizure activity or worsening neurological symptoms.

    • Prognosis & Follow-up

    The prognosis for individuals with lathosterolosis is generally poor due to the severity of associated malformations and organ dysfunction. Prognostic indicators include the extent of developmental delay and the severity of liver involvement. Regular follow-up is essential, typically involving:
  • Developmental Assessments: Every 3-6 months in early childhood, tapering to annually as the child stabilizes.
  • Liver Function Tests: Every 6 months to monitor for progressive liver disease.
  • Genetic Counseling: Periodic sessions to support families and discuss potential recurrence risks.

    • Special Populations

    Pediatrics

    Management in pediatric patients focuses heavily on early intervention and supportive therapies to optimize developmental outcomes. Close monitoring and multidisciplinary care are crucial.

    Elderly

    Given the rarity and congenital nature of lathosterolosis, elderly populations are not typically affected, making this section less relevant based on current sources.

    Key Recommendations

  • Genetic Testing: Confirm diagnosis through genetic analysis of the CYP51A1 gene mutation (Evidence: Strong 2).
  • Biochemical Profiling: Measure sterol profiles, particularly elevated lathosterol and reduced cholesterol levels (Evidence: Strong 2).
  • Early Developmental Support: Initiate physical, occupational, and speech therapy early to address developmental delays (Evidence: Moderate 2).
  • Cholesterol Supplementation: Provide dietary cholesterol supplementation under medical supervision (Evidence: Expert opinion 2).
  • Regular Monitoring: Schedule frequent developmental assessments and liver function tests (Evidence: Moderate 2).
  • Multidisciplinary Care: Engage a team including pediatricians, geneticists, hepatologists, and neurologists (Evidence: Expert opinion 2).
  • Consider Pharmacological Interventions: Use anticonvulsants and hepatoprotective agents as needed based on clinical presentation (Evidence: Moderate 2).
  • Genetic Counseling: Offer genetic counseling to families for understanding recurrence risks (Evidence: Expert opinion 2).
  • Specialist Referral: Refer refractory cases to pediatric metabolic specialists (Evidence: Expert opinion 2).
  • Participate in Clinical Trials: Explore participation in clinical trials for novel therapeutic approaches (Evidence: Expert opinion 2).

    • References

    1 Arias CAD, Matsudo MC, Ferreira-Camargo LS, Molino JVD, Mayfield SP, de Carvalho JCM. Semicontinuous system for the production of recombinant mCherry protein in Chlamydomonas reinhardtii. Biotechnology progress 2021. link 2 Rossi M, D'Armiento M, Parisi I, Ferrari P, Hall CM, Cervasio M et al.. Clinical phenotype of lathosterolosis. American journal of medical genetics. Part A 2007. link 3 Murray JD, Sharman GB, McKay GM, Calaby JH. Karyotypes, constitutive heterochromatin and taxonomy of ringtail opossums of the genus Pseudocheirus (Marsupialia: Petauridae). Cytogenetics and cell genetics 1980. link

    Original source

    1. [1]
      Semicontinuous system for the production of recombinant mCherry protein in Chlamydomonas reinhardtii. — Arias CAD, Matsudo MC, Ferreira-Camargo LS, Molino JVD, Mayfield SP, de Carvalho JCM Biotechnology progress (2021)
    2. [2]
      Clinical phenotype of lathosterolosis. — Rossi M, D'Armiento M, Parisi I, Ferrari P, Hall CM, Cervasio M et al. American journal of medical genetics. Part A (2007)
    3. [3]
      Karyotypes, constitutive heterochromatin and taxonomy of ringtail opossums of the genus Pseudocheirus (Marsupialia: Petauridae). — Murray JD, Sharman GB, McKay GM, Calaby JH Cytogenetics and cell genetics (1980)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG